- Home
- ACV vs LYEL Comparison
ACV vs LYEL Comparison
Compare ACV & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACV
- LYEL
- Stock Information
- Founded
- ACV 2015
- LYEL 2018
- Country
- ACV United States
- LYEL United States
- Employees
- ACV N/A
- LYEL N/A
- Industry
- ACV Finance/Investors Services
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- ACV Finance
- LYEL Health Care
- Exchange
- ACV Nasdaq
- LYEL Nasdaq
- Market Cap
- ACV 229.2M
- LYEL 207.7M
- IPO Year
- ACV N/A
- LYEL 2021
- Fundamental
- Price
- ACV $22.72
- LYEL $12.42
- Analyst Decision
- ACV
- LYEL Sell
- Analyst Count
- ACV 0
- LYEL 2
- Target Price
- ACV N/A
- LYEL $15.00
- AVG Volume (30 Days)
- ACV 38.8K
- LYEL 127.0K
- Earning Date
- ACV 01-01-0001
- LYEL 08-06-2025
- Dividend Yield
- ACV 9.20%
- LYEL N/A
- EPS Growth
- ACV N/A
- LYEL N/A
- EPS
- ACV N/A
- LYEL N/A
- Revenue
- ACV N/A
- LYEL $65,000.00
- Revenue This Year
- ACV N/A
- LYEL N/A
- Revenue Next Year
- ACV N/A
- LYEL N/A
- P/E Ratio
- ACV N/A
- LYEL N/A
- Revenue Growth
- ACV N/A
- LYEL N/A
- 52 Week Low
- ACV $16.82
- LYEL $7.65
- 52 Week High
- ACV $23.74
- LYEL $34.90
- Technical
- Relative Strength Index (RSI)
- ACV 59.52
- LYEL 67.30
- Support Level
- ACV $22.32
- LYEL $9.11
- Resistance Level
- ACV $22.84
- LYEL $9.83
- Average True Range (ATR)
- ACV 0.23
- LYEL 0.74
- MACD
- ACV -0.03
- LYEL 0.25
- Stochastic Oscillator
- ACV 68.53
- LYEL 84.54
About ACV Virtus Diversified Income & Convertible Fund of Beneficial Interest
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.